{"__slider":[],"__countdown":[{"gallery":[],"secstyle":"","imageObject":"202311161001179011.png","imageSecond":false,"sectionbg":"","background_image":false,"id":212,"title":"Regencell Bioscience Holdings Limited\u003Cbr\u003E Files Its 2022 Annual Report (Form 20-F)","subtitle":"","social":{"instagram":"","facebook":"","linkedin":"","youtube":""},"content":"\u003Cdiv class=\"_content\"\u003E\u003Cp style=\"text-align:justify\"\u003EHONG KONG, October 31, 2022 \u2014 Regencell Bioscience Holdings Limited (NASDAQ: RGC) (\u201cRegencell\u201d or the \u201cCompany\u201d), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine (\u201cTCM\u201d) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people\u2019s immune system, today announced that it filed its annual report on Form 20-F for the fiscal year ended June 30, 2022 (the \u201cAnnual Report\u201d) with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on the Company\u2019s investor relations website at https:\/\/www.regencellbioscience.com\/investor-relations\/ and on the SEC\u2019s website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to https:\/\/www.regencellbioscience.com\/investor-relations\/investor-contacts\/.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003ERegencell Bioscience Holdings Limited\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERegencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people\u2019s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formulae for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. For more information, please visit www.regencellbioscience.com and www.regencellasia.com.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003EForward-looking Statements\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThis press release contains \u201cforward\u2010looking statements\u201d within the meaning of applicable laws, including U.S. federal securities laws. These forward\u2010looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; statements that contain projections of results of operations or of financial condition; statements relating to the research, development, and use of our platform technologies, technologies, products and product candidates; and all statements that address activities, events, or developments that we intend, expect, project, believe, or anticipate will or may occur in the future. The risks and uncertainties of our company include: our ability to obtain regulatory approval and ultimately commercialize our TCM formulae and\/or products based on our TCM formulae; the outcome of our research study free from biases of parents or caregivers of patients because we relied on the data provided by them; difficulties enrolling patients in our research studies; any undesirable side effects caused by the TCM formulae candidates which could delay or prevent their regulatory approval or hinder commercialization; whether results of our earlier studies on personalized TCM formulae can be predictive of future research study results; failure of the research and development process; whether any TCM formulae candidates can be developed, manufactured, sold, marketed and distributed; the ability to successfully commercialize any future therapeutics; our ability to enhance our brand recognition; our ability to obtain and protect our intellectual property; and any adverse publicity associated with our TCM formulae candidates, ingredients or network marketing programs. We have based these forward\u2010looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. We have also relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources and makes no express or implied warranty as to the accuracy or completeness of any such information. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be indicative of results or developments in future periods. For a discussion of these and other risks and uncertainties, see our Annual Report on Form 20-F for the year ended June 30, 2022, which is available on the SEC\u2019s website at www.sec.gov. All information in this press release is as of the date of the release, and we undertake no duty to update this information unless required by law. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cbr \/\u003E\r\nContacts\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EInvestor Relations\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EJames Chung\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003Eir@rgcbio.com\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E+852 2155 0823\u003C\/p\u003E\u003C\/div\u003E","blurb":"","link":"","linktitle":"","links":[],"alink":"","buttons":"","imageObjectTitle":"","imageObjectSrc":"management.file\/img\/202311161001179011.png","imageObjectImg":"\u003Cdiv class=\"_imgobj p-r\"\u003E\u003Cimg src=\"management.file\/img\/202311161001179011.png\" \/\u003E\u003C\/div\u003E","imageObjectBg":"background-image: url(management.file\/img\/202311161001179011.png);","imageSecondTitle":"","imageSecondSrc":"","imageSecondImg":"","imageSecondBg":"","ittlsec":"\u003Cdiv class=\"_ittl\"\u003E\u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Ch4 class=\"h4\"\u003ERegencell Bioscience Holdings Limited\u003Cbr\u003E Files Its 2022 Annual Report (Form 20-F)\u003C\/h4\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\u003C\/div\u003E","h":"\u003Cdiv class=\"_ittl\"\u003E\u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Ch4 class=\"h4\"\u003ERegencell Bioscience Holdings Limited\u003Cbr\u003E Files Its 2022 Annual Report (Form 20-F)\u003C\/h4\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\u003C\/div\u003E","maintitle":"","sectitle":"\u003Cdiv class=\"_secttlbx\"\u003E\n \n \u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\n \n \u003Cdiv class=\"_ttlcontent _content\"\u003E\u003Cp style=\"text-align:justify\"\u003EHONG KONG, October 31, 2022 \u2014 Regencell Bioscience Holdings Limited (NASDAQ: RGC) (\u201cRegencell\u201d or the \u201cCompany\u201d), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine (\u201cTCM\u201d) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people\u2019s immune system, today announced that it filed its annual report on Form 20-F for the fiscal year ended June 30, 2022 (the \u201cAnnual Report\u201d) with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on the Company\u2019s investor relations website at https:\/\/www.regencellbioscience.com\/investor-relations\/ and on the SEC\u2019s website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to https:\/\/www.regencellbioscience.com\/investor-relations\/investor-contacts\/.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003ERegencell Bioscience Holdings Limited\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERegencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people\u2019s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formulae for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. For more information, please visit www.regencellbioscience.com and www.regencellasia.com.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003EForward-looking Statements\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThis press release contains \u201cforward\u2010looking statements\u201d within the meaning of applicable laws, including U.S. federal securities laws. These forward\u2010looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; statements that contain projections of results of operations or of financial condition; statements relating to the research, development, and use of our platform technologies, technologies, products and product candidates; and all statements that address activities, events, or developments that we intend, expect, project, believe, or anticipate will or may occur in the future. The risks and uncertainties of our company include: our ability to obtain regulatory approval and ultimately commercialize our TCM formulae and\/or products based on our TCM formulae; the outcome of our research study free from biases of parents or caregivers of patients because we relied on the data provided by them; difficulties enrolling patients in our research studies; any undesirable side effects caused by the TCM formulae candidates which could delay or prevent their regulatory approval or hinder commercialization; whether results of our earlier studies on personalized TCM formulae can be predictive of future research study results; failure of the research and development process; whether any TCM formulae candidates can be developed, manufactured, sold, marketed and distributed; the ability to successfully commercialize any future therapeutics; our ability to enhance our brand recognition; our ability to obtain and protect our intellectual property; and any adverse publicity associated with our TCM formulae candidates, ingredients or network marketing programs. We have based these forward\u2010looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. We have also relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources and makes no express or implied warranty as to the accuracy or completeness of any such information. Even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this presentation, they may not be indicative of results or developments in future periods. For a discussion of these and other risks and uncertainties, see our Annual Report on Form 20-F for the year ended June 30, 2022, which is available on the SEC\u2019s website at www.sec.gov. All information in this press release is as of the date of the release, and we undertake no duty to update this information unless required by law. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cbr \/\u003E\r\nContacts\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EInvestor Relations\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EJames Chung\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003Eir@rgcbio.com\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E+852 2155 0823\u003C\/p\u003E\r\n\u003C\/div\u003E\n \u003C\/div\u003E","iframe":"","date":"","documentSrc":"","document":"","documentTitle":"","videoSrc":"","video":"","videoTitle":""}],"__step":[],"__otherstep":[],"__textslide":[],"__message1":[],"__message2":[],"__gallery":[]}
